PT3829563T - Ácido 3-sulfopropanoico para tratamento de distúrbios neurodegenerativos - Google Patents

Ácido 3-sulfopropanoico para tratamento de distúrbios neurodegenerativos

Info

Publication number
PT3829563T
PT3829563T PT197527955T PT19752795T PT3829563T PT 3829563 T PT3829563 T PT 3829563T PT 197527955 T PT197527955 T PT 197527955T PT 19752795 T PT19752795 T PT 19752795T PT 3829563 T PT3829563 T PT 3829563T
Authority
PT
Portugal
Prior art keywords
methods
neurodegenerative disorders
treating neurodegenerative
treating
disorders
Prior art date
Application number
PT197527955T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of PT3829563T publication Critical patent/PT3829563T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PT197527955T 2018-08-01 2019-07-30 Ácido 3-sulfopropanoico para tratamento de distúrbios neurodegenerativos PT3829563T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862713061P 2018-08-01 2018-08-01

Publications (1)

Publication Number Publication Date
PT3829563T true PT3829563T (pt) 2025-02-18

Family

ID=67614642

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197527955T PT3829563T (pt) 2018-08-01 2019-07-30 Ácido 3-sulfopropanoico para tratamento de distúrbios neurodegenerativos

Country Status (27)

Country Link
US (2) US12083082B2 (cg-RX-API-DMAC7.html)
EP (1) EP3829563B1 (cg-RX-API-DMAC7.html)
JP (1) JP7573512B2 (cg-RX-API-DMAC7.html)
KR (1) KR102716959B1 (cg-RX-API-DMAC7.html)
CN (1) CN112867485A (cg-RX-API-DMAC7.html)
AU (1) AU2019315853B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001739A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021000269A1 (cg-RX-API-DMAC7.html)
DK (1) DK3829563T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190406A1 (cg-RX-API-DMAC7.html)
ES (1) ES3011716T3 (cg-RX-API-DMAC7.html)
FI (1) FI3829563T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250206T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070101T2 (cg-RX-API-DMAC7.html)
IL (1) IL280424B2 (cg-RX-API-DMAC7.html)
LT (1) LT3829563T (cg-RX-API-DMAC7.html)
MX (1) MX2021001287A (cg-RX-API-DMAC7.html)
MY (1) MY206530A (cg-RX-API-DMAC7.html)
PH (1) PH12021550213A1 (cg-RX-API-DMAC7.html)
PL (1) PL3829563T3 (cg-RX-API-DMAC7.html)
PT (1) PT3829563T (cg-RX-API-DMAC7.html)
RS (1) RS66516B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100767XA (cg-RX-API-DMAC7.html)
SI (1) SI3829563T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500080T1 (cg-RX-API-DMAC7.html)
UA (1) UA130011C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020028290A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.
PH12021553196A1 (en) * 2019-06-17 2022-11-07 Alzheon Inc Methods for treating neurodegenerative disorders
AU2022405026A1 (en) * 2021-12-09 2024-06-20 Alzheon, Inc. Alz-801 for use in treating alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
SI2089417T1 (sl) * 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
EP2852388A4 (en) 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2014121083A1 (en) * 2013-01-31 2014-08-07 President And Fellows Of Harvard College Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition
ES2960625T3 (es) * 2014-03-21 2024-03-05 Alzheon Inc Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+
EP3347002B1 (en) * 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.

Also Published As

Publication number Publication date
EP3829563A1 (en) 2021-06-09
US20250213507A1 (en) 2025-07-03
ES3011716T3 (en) 2025-04-08
EA202190406A1 (ru) 2021-10-15
BR112021001739A2 (pt) 2021-04-27
HUE070101T2 (hu) 2025-05-28
AU2019315853A1 (en) 2021-03-18
KR102716959B1 (ko) 2024-10-11
SMT202500080T1 (it) 2025-03-12
US12083082B2 (en) 2024-09-10
RS66516B1 (sr) 2025-03-31
LT3829563T (lt) 2025-02-25
CL2021000269A1 (es) 2021-06-18
PL3829563T3 (pl) 2025-04-07
IL280424B2 (en) 2025-01-01
SI3829563T1 (sl) 2025-05-30
MY206530A (en) 2024-12-19
SG11202100767XA (en) 2021-02-25
AU2019315853B2 (en) 2025-05-01
JP2021533128A (ja) 2021-12-02
MX2021001287A (es) 2021-07-15
EP3829563B1 (en) 2024-11-20
UA130011C2 (uk) 2025-10-15
CN112867485A (zh) 2021-05-28
IL280424B1 (en) 2024-09-01
KR20210039415A (ko) 2021-04-09
US20210315847A1 (en) 2021-10-14
PH12021550213A1 (en) 2021-11-03
FI3829563T3 (fi) 2025-02-17
CA3108150A1 (en) 2020-02-06
WO2020028290A1 (en) 2020-02-06
HRP20250206T1 (hr) 2025-04-11
DK3829563T3 (en) 2025-02-24
JP7573512B2 (ja) 2024-10-25
IL280424A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
IL267082A (en) Systems and methods for the treatment of neurological disorders
IL262222A (en) Anti-aging antibodies for the treatment of neurodegenerative disorders
IL273705A (en) Benzothiazole compounds and methods of using them for the treatment of neurodegenerative diseases
IL281052A (en) Treatment of liver disorders
PT3119911T (pt) Compostos para uso no tratamento da doença de alzheimer em pacientes apoe4+/+
SG10201913400QA (en) Methods for treating lung disorders
GB201803010D0 (en) Neurodegenerative disorders
ZA201800831B (en) Compositions and methods for treating and preventing neurodegenerative disorders
IL280424A (en) Methods for treating neurodegenerative disorders
SG11202007286TA (en) Methods for treating mitochondrial disorders
EP3313387A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
DK3829568T3 (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
IL286571A (en) Compounds and methods for the treatment of neurodegenerative disorders
GB201701404D0 (en) Therapies for treating inflammatory disorders
IL289018A (en) Methods for treating neurodegenerative disorders
HK40019969A (en) Compounds for use in methods for treating alzheimer&#39;s disease
HK40072836A (en) Methods for treating neurodegenerative disorders
HK40069546A (en) Methods for treating neurodegenerative disorders
HK40017730A (en) Methods for treating mitochondrial disorders
EP3246432A4 (en) Method for treating parts
PT3420084T (pt) Nova abordagem para tratamento de disfunções inflamatórias